Zenas BioPharma, Inc. Common Stock (ZBIO) — Financial Flexibility Index
Zenas BioPharma, Inc. Common Stock (ZBIO) has a Financial Flexibility Index of -0.16x as of December 2025. Free cash flow of $-22.41 Million (operating CF $-52.41 Million minus capex $30.00 Million) represents 0% of total liabilities ($141.50 Million). Also explore net asset growth rate of Zenas BioPharma, Inc. Common Stock to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Zenas BioPharma, Inc. Common Stock Financial Flexibility Index (2022–2025)
Historical Financial Flexibility Index trend for Zenas BioPharma, Inc. Common Stock across 4 annual periods. Check asset allocation strategy of Zenas BioPharma, Inc. Common Stock to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Zenas BioPharma, Inc. Common Stock (2022–2025)
Year-by-year free cash flow to debt coverage for Zenas BioPharma, Inc. Common Stock. For the full company profile including market capitalisation, see ZBIO market cap overview.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -1.22x | $-172.31 Million | $-172.33 Million | $141.50 Million | ▲ +41.4% |
| 2024 | -2.08x | $-119.54 Million | $-119.67 Million | $57.51 Million | ▼ -1902.2% |
| 2023 | -0.10x | $-30.51 Million | $-30.53 Million | $293.90 Million | ▲ +56.3% |
| 2022 | -0.24x | $-63.45 Million | $-65.65 Million | $266.87 Million | — |